These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6655567)

  • 1. A renal mechanism for the clofibric acid-probenecid interaction.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):739-42. PubMed ID: 6655567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):732-8. PubMed ID: 6655566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probenecid-clofibrate interaction.
    Veenendaal JR; Brooks PM; Meffin PJ
    Clin Pharmacol Ther; 1981 Mar; 29(3):351-8. PubMed ID: 7471606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.
    Rowe BJ; Meffin PJ
    J Pharmacol Exp Ther; 1984 Jul; 230(1):237-41. PubMed ID: 6747828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
    Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
    Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The simultaneous analysis of clofibric acid and probenecid and the direct analysis of clofibric acid glucuronide by high-performance liquid chromatography.
    Veenendaal JR; Meffin PJ
    J Chromatogr; 1981 Apr; 223(1):147-54. PubMed ID: 7251756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renal dysfunction on the individual components of the acyl-glucuronide futile cycle.
    Sallustio BC; Purdie YJ; Birkett DJ; Meffin PJ
    J Pharmacol Exp Ther; 1989 Oct; 251(1):288-94. PubMed ID: 2795462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography.
    Meffin PJ; Zilm DM
    J Chromatogr; 1983 Nov; 278(1):101-8. PubMed ID: 6662867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability studies of etofibrate in rhesus monkeys.
    Waller AR; Chasseaud LF; Taylor T; Schatton W
    Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.
    Vree TB; van den Biggelaar-Martea M; Verwey-van Wissen CP
    Br J Clin Pharmacol; 1995 Jun; 39(6):692-5. PubMed ID: 7654491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination.
    Miners JO; Robson RA; Birkett DJ
    Br J Clin Pharmacol; 1984 Aug; 18(2):240-3. PubMed ID: 6487463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probenecid-induced changes in the clearance of pranoprofen enantiomers.
    Imai T; Nomura T; Otagiri M
    Chirality; 2003 May; 15(4):318-23. PubMed ID: 12666238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation.
    Abernethy DR; Greenblatt DJ; Ameer B; Shader RI
    J Pharmacol Exp Ther; 1985 Aug; 234(2):345-9. PubMed ID: 4020675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.
    Zamboni WC; Houghton PJ; Johnson RK; Hulstein JL; Crom WR; Cheshire PJ; Hanna SK; Richmond LB; Luo X; Stewart CF
    J Pharmacol Exp Ther; 1998 Jan; 284(1):89-94. PubMed ID: 9435165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
    Jaehde U; Sörgel F; Reiter A; Sigl G; Naber KG; Schunack W
    Clin Pharmacol Ther; 1995 Nov; 58(5):532-41. PubMed ID: 7586947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species variation in the taurine conjugation of clofibric acid [proceedings].
    Caldwell J; Emudianughe TS; Smith RL
    Br J Pharmacol; 1979 Jul; 66(3):421P-422P. PubMed ID: 526711
    [No Abstract]   [Full Text] [Related]  

  • 17. Branched chain amino acid oxidation in cultured rat skeletal muscle cells. Selective inhibition by clofibric acid.
    Pardridge WM; Casanello-Ertl D; Duducgian-Vartavarian L
    J Clin Invest; 1980 Jul; 66(1):88-93. PubMed ID: 7400311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans.
    Shiga T; Hashiguchi M; Urae A; Kasanuki H; Rikihisa T
    Clin Pharmacol Ther; 2000 Mar; 67(3):222-8. PubMed ID: 10741624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
    Johnson KI; Hoppe HJ; Schatton W
    Arzneimittelforschung; 1984; 34(12):1785-7. PubMed ID: 6543315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic microsomal glucuronidation of clofibric acid in the adult and neonate albino rat.
    Odum J; Orton TC
    Biochem Pharmacol; 1983 Dec; 32(23):3565-9. PubMed ID: 6418177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.